STOCK TITAN

Nutriband Inc - NTRBW STOCK NEWS

Welcome to our dedicated news page for Nutriband (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nutriband's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nutriband's position in the market.

Rhea-AI Summary
Nutriband Inc. announces the development of AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal patch, through a 505(b)(2) New Drug Application (NDA) pathway. Partnering with Kindeva Drug Delivery, Nutriband aims to revolutionize the opioid market by incorporating their AVERSA™ technology into FDA-approved transdermal fentanyl patches. The NDA submission will be based on a single Phase 1 human abuse potential clinical study, eliminating the need for Phase 2 or 3 trials. This streamlined regulatory process could lead to expedited FDA review, potentially making AVERSA™ Fentanyl the first abuse-deterrent patch approved globally. Market analysis projects peak annual US sales of $80 million to $200 million for AVERSA™ Fentanyl, tapping into the $22.8 billion global opioid market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.22%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. announces the development of AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal patch, through a 505(b)(2) New Drug Application (NDA) pathway. Partnering with Kindeva Drug Delivery, Nutriband aims to revolutionize the opioid market by incorporating their AVERSA™ technology into FDA-approved transdermal fentanyl patches. The NDA submission will be based on a single Phase 1 human abuse potential clinical study, eliminating the need for Phase 2 or 3 trials. This streamlined regulatory process could lead to expedited FDA review, potentially making AVERSA™ Fentanyl the first abuse-deterrent patch approved globally. Market analysis projects peak annual US sales of $80 million to $200 million for AVERSA™ Fentanyl, tapping into the $22.8 billion global opioid market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
90.51%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. presents data on transdermal patch abuse and accidental pediatric exposure at the 2024 AAPM Annual Meeting. The company's AVERSA™ technology aims to provide safer abuse-deterrent transdermal patches for opioid and stimulant drugs, addressing a critical unmet need in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
Rhea-AI Summary
Nutriband Inc. presents data on transdermal patch abuse and accidental pediatric exposure at the 2024 AAPM Annual Meeting. The company's AVERSA™ technology aims to provide safer abuse-deterrent transdermal patches for opioid and stimulant drugs, addressing a critical unmet need in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.56%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. announces data on transdermal patch abuse and accidental exposure to be presented at the 2024 AAPM Annual Meeting. The company collaborated with RMPDS to determine abuse rates in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. (NTRB) is set to present at The Microcap Conference in Atlantic City from January 30th to February 1st. CEO Gareth Sheridan will deliver two presentations and address questions. The company aims to showcase its potential to investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
conferences
Rhea-AI Summary
Nutriband Inc. (NTRB) is set to present at The Microcap Conference in Atlantic City from January 30th to February 1st. CEO Gareth Sheridan will deliver two presentations and address questions. The company aims to showcase its potential to investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.88%
Tags
conferences
-
Rhea-AI Summary
Nutriband Inc. CEO Gareth Sheridan published a letter to shareholders outlining the company's achievements in 2023 and targets for 2024. The company made significant strides in developing transdermal pharmaceutical products, securing new IP, and signing a commercial development and clinical supply agreement with Kindeva Drug Delivery for AVERSA Fentanyl, estimated to potentially reach peak annual sales of $80M - $200M. The company also reported strong revenue growth in 2023 and aims to expand its revenue opportunities through marketing initiatives and new product launches in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. CEO Gareth Sheridan published a letter to shareholders outlining the company's achievements in 2023 and targets for 2024. The company made significant strides in developing transdermal pharmaceutical products, securing new IP, and signing a commercial development and clinical supply agreement with Kindeva Drug Delivery for AVERSA Fentanyl, estimated to potentially reach peak annual sales of $80M - $200M. The company also reported strong revenue growth in 2023 and aims to expand its revenue opportunities through marketing initiatives and new product launches in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.94%
Tags
none
Rhea-AI Summary
Nutriband Inc. (NTRB) announced a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with Kindeva Drug Delivery. The agreement aims to support a New Drug Application (NDA) with the FDA, replacing a previous feasibility agreement. Aversa™ Fentanyl is estimated to have the potential to reach peak annual US sales of $80M - $200M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.14%
Tags
none
Nutriband Inc

Nasdaq:NTRBW

NTRBW Rankings

NTRBW Stock Data

4.01M
All Other Miscellaneous Chemical Product and Preparation Manufacturing
Manufacturing
Link
US
Orlando

About NTRBW

nutriband inc. is a health and pharmaceutical company based in, oviedo, florida. nutriband's primary focus is on transdermal and topical technologies for product development.